Online Registration is Open!
Printed from the IBC Life Sciences Web site on June 19, 2013 2:50 PM ET.
Page location: http://www.ibclifesciences.com/ProteinSummit/overview.xml
June 26-28, 2013 · Hotel del Coronado · Coronado, CA
Early Registration Discounts
are Ending May 31st
» View pricing and saving details
FDA Perspective on Novel Monoclonal Antibody Development Pathways
Kathleen A. Clouse, Ph.D., Director, Division of Monoclonal Antibodies OBP, CDER, US FDA
Protein Engineering with an Expanded Genetic Code
Peter G. Schultz, Ph.D., Professor of Chemistry, The Scripps Research Institute; Founding Director, California Institute for Biomedical Research
Antibody-Drug Conjugates: Current and Future Developments
Hans-Peter Gerber, Ph.D., Executive Director, BioConjugates Discovery and Development, Oncology Research, Pfizer Inc.
Challenges and Opportunities in Developing Scaffold Therapeutics in an Antibody World
Manuel Baca, Ph.D., Fellow, Antibody Discovery & Protein Engineering, MedImmune, LLC
Optimization and Safety of Transfer'rin Bispecifics across the Blood-Brain Barrier
Mark S. Dennis, Principal Scientist, Antibody Engineering, Genentech, Inc.
See what we have added to the Summit for 2013!
Special Discounted Hotel Rate Available Until June 4, 2013. To book your room, call 800-468-3533 and mention that you are an IBC attendee at this event.
Read what past attendee's had to say...
For eight years running, IBC's Next Generation Protein Therapeutics Summit has been the industry's most innovative and comprehensive conference for sharing best practices and new ideas to accelerate the discovery, engineering and development of alternative scaffolds and novel protein therapeutics, and this year is no exception.
No other conference on the market consistently brings together world-renowned academic scientists and top industry speakers from diverse disciplines to explore the complexities and find solutions to the unique challenges of protein therapeutic drug development.
Cross-fertilization of new ideas from different fields is often the key to success in drug development and this year's conference features over 85% new speakers and content including three new conference themes.
"This was by far the best conference on therapeutic proteins over the last 7 years. Well done, superb program!" - Fredrik Frejd, Senior Scientist, Affibody, Sweden
Below is just a sample of the exciting new science you will hear by attending:
Please join us this June at the beautiful Hotel del Coronado near San Diego for this information-packed conference. This exciting event provides you with new ideas and practical strategies for protein therapeutic design and development that you can take home right away and apply in your own laboratory.
These two conferences have been developed for scientists, managers and directors working in Discovery/R&D, Chemistry/ Conjugation, Biochemistry, Protein and Antibody Engineering and Biotherapeutic Development.
"The depth and breadth of the presentations was fantastic covering all aspects of the "Beyond Antibody" landscape from discovery to the clinic" - Michelle Schaeffer, Scientist II, Zyngenia